SCHEMBL5879095

SCHEMBL5879095

N#CC(I)=CCCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
CASP1 P29466 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
GPR52 Q9Y2T5 4/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
KEAP1 Q14145 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP2A6 P11509 1/20 0.34
HTR2A P28223 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9901355 0.81 GRIK1 (0.42) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL3440751 0.78 ALDH1A1 (0.41) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL3440752 0.78 ALDH1A1 (0.41) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL14312304 0.78 ALDH1A1 (0.41) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL1274448 0.75 GRIK1 (0.49) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL7168307 0.73 TDP1 (0.50) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL7639052 0.70 TDP1 (0.46) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL7525775 0.70 ALDH1A1 (0.42) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL105976 0.70 TRPV1 (0.51) GRIK1ALDH1A1HPGDALOX15ALOX12
SCHEMBL6053648 0.70 TDP1 (0.46) GRIK1ALDH1A1HPGDALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034056-B2 Aryl and biaryl compounds having MCH modulatory activity PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2006-04-25 US disclosed
EP-1370520-A1 ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2003-12-17 EP disclosed
US-20030092715-A1 Aryl and biaryl compounds having MCH modulatory activity SCHERING CORPORATION 2003-05-15 US disclosed
WO-2002076929-A1 ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092715-A1 Aryl and biaryl compounds having MCH modulatory activity MCHR1, MCHR2, MC3R GRIK1 980/4885ALDH1A1 1069/4885HPGD 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.